Contact:
Elizabeth L.R. Donley, CEO
Stemina Biomarker Discovery, Inc.
608-577-9209
bdonley@stemina.com
BIO Investor Forum to be held October 8-9 in San Francisco, Calif.
October 7, 2013, San Francisco, CA, October 8, 2013] – Stemina Biomarker Discovery announced that Elizabeth Donley, Chief Executive Officer of Stemina Biomarker Discovery, will be presenting at the 12th Annual BIO Investor Forum. Hosted by the Biotechnology Industry Organization (BIO), the 12th Annual BIO Investor Forum features leading private and emerging public companies. The meeting will take place October 8-9 at the Palace Hotel in San Francisco, Calif.
“We are very pleased to be invited to present at the Bio Investors Forum funded by the National Science Foundation” said Elizabeth Donley.
Stemina has received more than $1.2 million in funding from NSF to develop its toxicology test, devTOX, which helps prevent birth defects by assessing whether a drug candidate or new chemical compound will cause birth defects if a woman is exposed during pregnancy.
In addition, Stemina is using its proprietary metabolomics platform technology to develop a blood test for diagnosis and personalized treatment of autism spectrum disorders. Stemina’s biochemical approach allows diagnosis across the spectrum without regard to genetics or other causes. This unique approach will allow development of new therapies, companion diagnostics and identification of the best treatment for an individual patient based on their own biochemistry.
Stemina is seeking to raise its first round of venture capital to accelerate its diagnostic test for autism to market and to ramp up capacity on its devTox assay which is generating revenue currently by providing testing to pharmaceutical, agri-chemical and chemical companies as well as the US government.
ABOUT STEMINA BIOMARKER DISCOVERY
Stemina Biomarker Discovery began operations in November 2007. Stemina develops predictive models for toxicology and is developing a blood test for diagnosis and personalized treatment of autism using its metabolomics based biomarker discovery platform. Located in Madison, Wisconsin, Stemina’s cell based assays arise from the strategic convergence of two cutting edge technologies: stem cells and metabolomics. Stemina uses mass spectrometry to analyze the small molecules secreted by cells and in patient samples in response to drugs, injury or disease. Stemina is a recognized leader in hES based toxicology and safety.
For more information about Stemina, visit http://www.stemina.com.
ABOUT THE BIO INVESTOR FORUM
The 12th Annual BIO Investor Forum is an international investor conference focused on private and emerging public biotech companies. Because our mission is to support industry-wide success, we present a broad and unbiased view of investment opportunities. In addition, the BIO Investor Forum draws business development executives from leading global pharmaceutical and established biotechnology companies.
